Journal · News
REMAIN-1 (2026): Can a Procedure Limit Weight Regain After Stopping Tirzepatide?
Fractyl Health's topline REMAIN-1 data suggest one endoscopic procedure reduced regain after tirzepatide, but the results are company-reported, the device is not authorized in the US, and staying on treatment still has its own price.
Fractyl Health reported on October 16, 2026 that in its REMAIN-1 pivotal study, adults who stopped tirzepatide after losing at least 15% regained 5.1% of body weight at 6 months after one Revita procedure, versus 8.2% after a sham procedure (p=0.0023). These are company-reported topline results, and Revita remains investigational in the US.
The results are not peer reviewed, the 12-month co-primary endpoint is due in Q1 2027, the study excluded people with diabetes, and no price for the procedure has been published.
What did REMAIN-1 report?
On October 16, 2026, Fractyl Health said its REMAIN-1 pivotal study met its 6-month co-primary endpoint. People who stopped tirzepatide and then had one Revita procedure regained 5.1% of body weight on average at 6 months. People who had a sham procedure regained 8.2% (p=0.0023). The release, filed with the SEC the same day, calls these "topline six-month results" (Fractyl Health press release, SEC Exhibit 99.1).
| Measure | Revita | Sham procedure | Note |
|---|---|---|---|
| Mean weight regain at 6 months (least-squares mean) | 5.1% | 8.2% | p=0.0023; co-primary endpoint |
| Share of tirzepatide weight loss kept at 6 months | About 80% | About 67% | Company estimate |
| Weight stable or still losing (under 2% regain) | 32% | 18% | Post hoc; nominal p=0.020 |
| Participants in the 6-month figures | 176 | 74 | Release also cites an mITT population of 308 |
Three cautions before you lean on these numbers:
- Not peer reviewed. We found no journal publication as of November 9, 2026. The figures come from the company.
- The counts don't add up cleanly. The release describes a modified intention-to-treat population of 308 but lists 176 Revita and 74 sham participants, 250 in total, for the 6-month figures. It doesn't explain the gap.
- Some findings are exploratory. The 32% versus 18% result and the analyses by treated length of the duodenum are labelled post hoc, with nominal p-values. Key secondary endpoints are only tested formally after the 12-month endpoint.
On safety, the company reported no device- or procedure-related serious adverse events, no deaths and no unanticipated adverse device effects as of a September 24, 2026 data cut-off. It said 94% of related adverse events happened within 7 days of the procedure.
How was REMAIN-1 designed?
REMAIN-1 is registered as NCT06484114. The registry describes a randomized, double-blind, sham-controlled pivotal study, with participants, care providers and outcome assessors masked (REMAIN-1 on ClinicalTrials.gov).
- Who: adults aged 21 to 70 with a BMI of 30 to 45 before tirzepatide, without type 1 or type 2 diabetes; the company says more than 30 US sites took part.
- Lead-in: everyone took tirzepatide and had to lose at least 15% of body weight.
- Then: they stopped tirzepatide and were randomized 2:1 to one Revita procedure or a sham endoscopy with a non-active catheter.
- Endpoints: percent weight change at week 26, Revita versus sham (now reported as met), and the share of Revita patients keeping at least 5% loss from their pre-tirzepatide weight at week 52, against an FDA performance goal of more than 50%.
Revita is a one-time endoscopic procedure that the company says is "designed to remodel the duodenal lining," a technique called duodenal mucosal resurfacing. The duodenum is the first part of the small intestine. The 12-month results are expected in the first quarter of 2027; the registry lists an estimated primary completion date of February 15, 2027.
How does REMAIN-1 compare with SURMOUNT-4?
SURMOUNT-4 is the reference trial for stopping tirzepatide (SURMOUNT-4 in JAMA, 2024). Of 783 adults who started a 36-week open-label lead-in on their maximum tolerated dose of 10 or 15 mg, 670 were randomized. They had lost 20.9% of body weight on average. Over the next 52 weeks:
- People switched to placebo regained 14.0% of body weight.
- People who stayed on tirzepatide lost a further 5.5%.
- 89.5% of the tirzepatide group kept at least 80% of their lead-in loss, compared with 16.6% of the placebo group.
Both trials point the same way: on average, weight comes back after tirzepatide stops. REMAIN-1's sham group regained 8.2% in 6 months; SURMOUNT-4's placebo group regained 14.0% in 12 months.
Don't compare those two numbers directly. The entry rules differ (at least 15% loss versus reaching the top tolerated dose), the control differs (sham endoscopy versus placebo injections), and so does the length.
What REMAIN-1 adds is a randomized, sham-controlled signal that a procedure, rather than continued medication, may slow regain over 6 months. What it doesn't show: the Revita group still regained weight on average, and there is no head-to-head comparison with staying on tirzepatide, which in SURMOUNT-4 led to further loss. For more on the withdrawal data, see our SURMOUNT-4 trial review and what happens after you stop tirzepatide.
Who do the results apply to?
A narrower group than most people on tirzepatide. To be randomized, participants had to lose at least 15% of body weight on the drug. In SURMOUNT-1, 48.0% to 70.6% of people on tirzepatide 5 to 15 mg reached a 15% loss after 72 weeks, according to the Zepbound label. The rest would not have qualified.
- No diabetes. People with type 1 or type 2 diabetes were excluded, so the results say nothing about them.
- BMI 30 to 45 before treatment. People with a BMI above 45, or with overweight below 30, were not studied.
- Six months only, so far. SURMOUNT-4 measured regain over a full year. The 12-month REMAIN-1 data will show whether the gap between the groups holds.
Is Revita FDA-approved?
No. The company states that Revita is for investigational use only in the US. It has FDA Breakthrough Device designation for weight maintenance after stopping GLP-1 therapy, and it is CE marked in the European Union and the United Kingdom.
Breakthrough designation is not an authorization. The FDA describes the program as "a voluntary program for certain medical devices" and says breakthrough devices must still meet its standards for safety and effectiveness (FDA Breakthrough Devices Program).
Fractyl's stated timeline:
- Late Q4 2026: planned De Novo submission to the FDA. The company says the FDA will make final pathway decisions after reviewing the full safety data.
- January 1, 2027: Category III CPT code 1122T takes effect.
- Q1 2027: topline 12-month data, including the second co-primary endpoint.
- Late 2027: potential marketing authorization; early 2028: potential US launch.
The release says coding, coverage and payment "are not assured." It gives no price for the procedure.
What does staying on tirzepatide cost compared with stopping?
Another year costs $1,512 to $1,548 month to month at the three $126 to $129 programs below and $5,837 for Zepbound self-pay at 7.5 to 15 mg; stopping costs $0 in medication. The compounded rows are cash prices; compounded tirzepatide is made with the drug in Zepbound, not the same product, and the FDA says compounded drugs are not FDA-approved (FDA's concerns with unapproved GLP-1 drugs).
| Program and basis | Price read | 6 months (USD) | 12 months (USD) | Source domain, read date |
|---|---|---|---|---|
| NexLife, month to month | $129 a month | 774 | 1,548 | nexlife.us, Nov 20, 2026 |
| NexLife, 6- or 12-month plan | $119 a month (6 months); $115 a month (12 months) | 714 | 1,380 | nexlife.us, Nov 20, 2026 |
| Eden | $129 every month, no membership | 774 | 1,548 | eden.health, Oct 15, 2026 |
| Mondae | $126 month to month | 756 | 1,512 | mondae.com, Oct 15, 2026 |
| TelePep, month to month | $249 a month | 1,494 | 2,988 | telepeptide.org, Oct 15, 2026 |
| TelePep, prepaid | $1,344 for 6 months; $2,568 for a year, upfront | 1,344 | 2,568 | telepeptide.org, Oct 15, 2026 |
| Zepbound self-pay, 7.5 to 15 mg | $449 per 28-day fill, refill within 45 days; 6 fills vs 13 fills | 2,694 | 5,837 | lilly.com, Nov 9, 2026 |
| Stopping | No medication cost; Revita is not available outside trials in the US | 0 | 0 | — |
Notes on the rows: Eden's $129 a month equals NexLife's month-to-month price. Lilly's self-pay terms say 7.5 to 15 mg costs $449 only if each refill comes within 45 days, otherwise $499 (7.5 mg) or $699 (10 to 15 mg), and that the savings end December 31, 2026 (Zepbound coverage and savings). The label lists 5, 10 or 15 mg as maintenance doses (Zepbound prescribing information); at 5 mg a fill is $399. More programs are in our provider pricing data.
What this means for you
Example 1: what the averages look like in pounds. Say you started at 240 lb and lost 20%, or 48 lb, reaching 192 lb. If the reported regain is measured from the weight at stopping (the release doesn't say), 8.2% of 192 lb is about 15.7 lb and 5.1% is about 9.8 lb, a gap of about 6 lb. SURMOUNT-4's 14.0% would be about 26.9 lb over a year. These are trial averages, not predictions for you.
Example 2: a year of staying on. At $129 a month, 12 months cost $1,548. NexLife's 12-month plan totals $1,380, which is $168 less. Thirteen 28-day Zepbound fills at $449 cost $5,837, or $4,457 more than $1,380.
Example 3: waiting for Revita. The company's earliest potential US launch is early 2028. From December 2026 through December 2027 is 13 months. At $129 a month, that is 13 × $129 = $1,677, if today's prices hold, which no program promises.
Example 4: a 6-month bridge. If you and your prescriber plan to stop in spring, 6 more months at NexLife cost $774 month to month or $714 on the 6-month plan. NexLife's plan pages say cancellations take effect after 30 days, so one more shipment may be charged.
For full-year math across programs, see the annual cost of tirzepatide.
What should you weigh if you plan to stop?
- Make it a plan with your prescriber, including a weigh-in schedule and a weight at which you would restart or change treatment. Our guide to stopping a GLP-1 lists the questions to ask.
- Don't count on Revita yet. It is investigational in the US, the 12-month endpoint is pending, no price has been published and coverage is not assured.
- Know what wasn't tested. Neither trial, as published or registered, compares a gradual taper with stopping; SURMOUNT-4 switched people straight to placebo.
- Check billing before you cancel. Notice periods and prepaid terms change the real cost of stopping; month-to-month terms are covered in tirzepatide month to month.
Questions readers ask
What is REMAIN-1?
REMAIN-1 (NCT06484114) is a randomized, double-blind, sham-controlled pivotal study run by Fractyl Health. Adults with a BMI of 30 to 45 and no diabetes took tirzepatide until they lost at least 15% of body weight, then stopped and were randomized 2:1 to a single Revita endoscopic procedure or a sham procedure. It tests whether Revita reduces weight regain after stopping the drug.
Can I get Revita now?
Not in the US outside a clinical trial. Fractyl says Revita is for investigational use only in the US. It holds FDA Breakthrough Device designation, which is not an approval. The company plans a De Novo submission in late 2026 and gives early 2028 as a potential US launch, but coverage and payment are not assured and no price has been published.
How much weight do people regain after stopping tirzepatide?
In SURMOUNT-4, published in JAMA in 2024, people switched to placebo after a 36-week lead-in regained 14.0% of body weight over 52 weeks, while those who continued lost a further 5.5%. In REMAIN-1, the sham group regained 8.2% at 6 months, according to the company. The trials had different entry rules and controls, so the numbers are not directly comparable.
Are the REMAIN-1 results peer reviewed?
Not as of November 9, 2026. Fractyl Health released them on October 16, 2026 as topline six-month results in a press release that it also filed with the SEC. Several analyses in the release are labelled post hoc with nominal p-values, and the second co-primary endpoint, at 12 months, is expected in the first quarter of 2027.
How much does it cost to stay on tirzepatide for another year?
It depends on the program and product. At $129 a month, 12 months cost $1,548; NexLife's 12-month plan totals $1,380 (prices read November 20, 2026), and Eden also charges $129 a month (read October 15, 2026). Zepbound self-pay at 7.5 to 15 mg costs $5,837 for thirteen 28-day fills if each refill qualifies for the $449 price.
Sources
- Fractyl Health, Inc., filed with the U.S. Securities and Exchange Commission (EDGAR). Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study (press release, Form 8-K Exhibit 99.1) (2026-10-16). Read November 9, 2026.
- ClinicalTrials.gov, U.S. National Library of Medicine. REMAIN-1: Safety and efficacy of Revita DMR for body weight maintenance after at least 15% weight loss on tirzepatide (NCT06484114) (2026-03-03 (last update posted)). Read November 9, 2026.
- JAMA (full text via PubMed Central). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial, JAMA 2024;331(1):38-48, DOI 10.1001/jama.2023.24945 (2023-12-11 (online); 2024-01-02 (issue)). Read November 9, 2026.
- U.S. Food and Drug Administration. Breakthrough Devices Program (2026-08-31 (content current as of)). Read November 9, 2026.
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (2026-10-01 (content current as of)). Read November 9, 2026.
- Eli Lilly and Company. Zepbound coverage and savings (Zepbound Self-Pay Savings Card terms) (offer ends 2026-12-31 (no page date shown)). Read November 9, 2026.
- DailyMed, U.S. National Library of Medicine (label by Eli Lilly and Company). ZEPBOUND (tirzepatide) injection, prescribing information (2026-08 (revised); 2026-09-02 (DailyMed version 40)). Read November 9, 2026.